Soluble TWEAK and cardiovascular morbidity and mortality in chronic kidney disease patients.

@article{Hassan2012SolubleTA,
  title={Soluble TWEAK and cardiovascular morbidity and mortality in chronic kidney disease patients.},
  author={Seham Bakry Hassan and Ahmed Bahgat El-demery and Asmaa Ismail Ahmed and Reham Emad Abukhalil},
  journal={Arab journal of nephrology and transplantation},
  year={2012},
  volume={5 1},
  pages={27-32}
}
INTRODUCTION Cardiovascular disease (CVD) is a major cause of morbidity and mortality in chronic kidney patients (CKD). The aim of this study was to demonstrate the role of soluble tumor necrosis factor (TNF) weak inducer of apoptosis (sTWEAK) as a marker of cardiovascular morbidity and mortality in CKD patients. METHODS The study included 75 CKD patients classified according to eGFR into three groups; group-1 included 15 patients with stage-1 CKD, group-2 included 30 patients with stage-2… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 26 references

Atherosclerosis: should we stop TWEAKing it?

Arteriosclerosis, thrombosis, and vascular biology • 2009

Similar Papers

Loading similar papers…